Related Experiment Video
Updated: Aug 15, 2026
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Quantification of Ocular Gene Therapy-Related Inflammation Using the VRMACS Grading System
Maram E A Abdalla Elsayed1,2, Robert E MacLaren1,2
1Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Ophthalmology Science
|August 14, 2026
Summary
A new grading system, the VRMACS score, standardizes the assessment of retinal inflammation after gene therapy. This framework improves safety monitoring and clinical trial consistency for ocular gene therapy treatments.
Area of Science:
- Ophthalmology
- Gene Therapy
- Inflammation Research
Background:
- Inherited retinal degenerations are treatable with gene therapy, with potential for common conditions like AMD and DR.
- Ocular gene therapy faces limitations due to inflammation, a factor in dose-limiting toxicity and inconsistent safety assessments across trials.
- Current methods for grading retinal inflammation are not standardized, hindering cross-study comparisons and reliable safety evaluations.
Purpose of the Study:
- To address the lack of a standardized system for grading retinal inflammation in ocular gene therapy.
- To propose a reproducible framework for assessing and reporting inflammation following retinal gene therapy.
- To enhance the consistency and reliability of safety assessments in gene therapy clinical trials.
Main Methods:
- Synthesized evidence from published retinal gene therapy studies reporting inflammatory outcomes.
- Integrated data from a dedicated gene therapy center's clinical experience.
- Developed the Vitritis, Retinitis, Microperimetry changes, Fundus Autofluorescence abnormalities, Choroiditis, and Subretinal infiltrates (VRMACS) score, a novel grading framework.
Main Results:
- The proposed VRMACS score evaluates six key domains: vitritis, retinitis, microperimetry changes, fundus autofluorescence abnormalities, choroiditis, and subretinal infiltrates.
- This grading system allows for structured, longitudinal assessment of inflammatory severity after gene therapy.
- The VRMACS score offers a standardized method to improve detection, quantification, and reporting of inflammation in subretinal ocular gene therapy.
Conclusions:
- The VRMACS score provides a standardized grading system for retinal inflammation, crucial for ocular gene therapy.
- Standardized inflammation grading can aid dose selection, define stopping rules, and ensure consistent safety assessment across clinical trials.
- Clinically, the VRMACS score serves as a practical tool for monitoring patients and guiding timely interventions in retinal gene therapy.
